{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-221596","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2026-05-13T20:05:34+00:00","discovered_at":"2026-05-13T20:07:00.323726+00:00","generated_at":"2026-05-13T22:10:09.272753+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M","bullets":["Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.","Neurosurgery navigation revenue surged 80% to $5.9M, driven by IRRA flow and 3.0 software adoption.","Biologics & drug delivery revenue stable at $4.8M; over 60 active biopharma partners enrolled.","Cash and equivalents $35.6M at Mar 31, 2026; expects cash burn to reduce in H2 2026 from cost synergies.","FDA cleared Velocity Alpha drill used in first clinical procedure; Health Canada MDL license obtained."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-221596","json":"https://secwatch.observer/filing/0001193125-26-221596.json","markdown":"https://secwatch.observer/filing/0001193125-26-221596.md","text":"https://secwatch.observer/filing/0001193125-26-221596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000119312526221596/0001193125-26-221596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000119312526221596/clpt-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:10:09.272753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}